Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention
of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5–10 …

Sir, Mutations in the pyrin gene (MEFV) cause the inflammatory disorder familial
Mediterranean fever (FMF)[1]. Most of the patients are treated with colchicine for the …

Familial Mediterranean fever (FMF), a recessively inherited autoinflammatory disorder, is the
prototype of a group of disorders termed systemic autoinflammatory diseases. Such …

Familial Mediterranean fever (FMF) is the most common autoinflammatory disease
worldwide. Approximately 5–10% of patients are unresponsive to colchicine. Aim of this …

Familial Mediterranean fever (FMF) is the most common form of monogenic
autoinflammatory conditions, and response to colchicine has been considered as one of its …

Prophylactic colchicine therapy has been shown to be a safe and effective method of
eliminating the attacks and preventing the development of amyloidosis in patients with …

The daily application of colchicine is the standard therapy for prophylaxis of attacks and
amyloid deposition in familial Mediterranean fever. However, because of many issues (eg …

Objective. Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory
disorder characterized by recurrent attacks of fever and serositis. Although colchicine is the …

Colchicine is the treatment of choice in familial Mediterranean fever (FMF) both for attacks
and for prevention of seconda ry amyloidosis. The ove ra ll non-responder rate varies from 5 …

Familial Mediterranean fever (FMF) is the prototype of auto-inflammatory disorders and is
ethnically restricted to people living in the Mediterranean basin and Middle-East. Pyrin, the …